The Democratic Republic of the Congo faces its second-largest and fastest-growing Ebola outbreak on record, driven by the rare Bundibugyo strain. As the death toll surpasses 1,700, the World Health Organization and international partners have accelerated clinical trials for experimental treatments, preventive drugs, and mRNA vaccines in Canada and the U.K.
The outbreak, officially declared on May 15, has quickly outpaced historical benchmarks. According to the latest government figures cited by Aljazeera, the virus has recorded 3,802 cases and 1,707 deaths. Unlike previous epidemics, this outbreak involves the Bundibugyo variant, which carries no approved vaccines or targeted treatments.
Health officials note that transmission is moving faster than containment resources can be deployed.
International Vaccine Trials Expand to Canada and the UK
In response to the unprecedented spread, vaccine research has entered clinical phases abroad. Health Canada authorized Moderna to launch a Phase 1 clinical trial for an experimental mRNA-based vaccine targeting the Bundibugyo strain. Bloomberg notes that the single-shot vaccine is being tested in about 80 healthy adults in Canada, with initial safety and immune-response data anticipated in the coming months, according to Bloomberg.com.
Federal regulators in Canada emphasized that the authorization requires rigorous oversight. Officials stated that following this, Moderna would be required to conduct additional clinical trial phases before it could seek approval from Health Canada for the vaccine,
and that any final submission must meet Health Canada’s stringent safety, efficacy and quality standards before the vaccine could be allowed on the Canadian market,
as detailed by CBC.
This trial follows a separate Phase 1 evaluation launched in Britain on July 24 for a Bundibugyo-specific vaccine developed by Oxford University and the Serum Institute of India, as reported by Reuters. Additionally, the World Health Organization is reviewing new animal data to determine whether Merck’s licensed Zaire-strain vaccine might provide cross-protection against the Bundibugyo variant.
Treatment and Prophylaxis Studies Underway in Ituri Province
On the ground in the Democratic Republic of the Congo, experimental therapeutics and prophylaxis studies are actively recruiting participants. The outbreak is concentrated in the eastern province of Ituri, which accounts for nearly 90 percent of reported cases, though infections have also been confirmed in five other provinces, including the major city of Kisangani, according to Aljazeera.
A WHO-sponsored treatment trial operates at three clinical management facilities in Ituri province in partnership with medical charities ALIMA and Doctors Without Borders, enrolling more than 50 confirmed Ebola patients into randomized experimental treatment arms. Simultaneously, a prophylaxis study led by Congo’s National Institute for Biomedical Research is testing whether a 10-day course of the oral antiviral drug obeldesivir can prevent disease in high-risk contacts, with more than 25 participants enrolled, as noted by Reuters and medicalxpress.com.
“If you compare this outbreak to previous Ebola outbreaks, we have been able to start trials more quickly. It’s true that the preclinical data that we’re seeing is promising.”
Vasee Moorthy, acting head of the WHO’s R&D Blueprint programme
Despite the rapid deployment of research protocols, Vasee Moorthy cautioned that only clinical trials will definitively establish whether these experimental medicines and vaccines are effective.
Logistical Obstacles and Community Spread Hinder Containment
Health authorities face severe hurdles in curbing the transmission chain. Africa CDC Director-General Jean Kaseya cautioned during a visit to Bunia that it remained unclear when the outbreak would reach its peak.
Response efforts are further constrained by security risks. Al Jazeera reported that the medical mission has been hampered by delays in contact tracing, violence from armed groups, attacks on health facilities, and widespread community mistrust. Over 100 healthcare workers have been infected since the epidemic began. Operational pressures have also triggered labor unrest; frontline personnel in Mongbwalu and Bunia have staged strikes or issued ultimatums over unpaid wages and dangerous working conditions.
- NHS Guidelines for Under-50 Breast Cancer Miss Most At-Risk Women
- USC Dornsife and Howard University Study Links Ancient Genes to Severe Covid
- Russian soldier kills fellow troop and three civilians in Crimea: report (newsylist.com)
- Soldier kills four in gun rampage in Russian-occupied Crimea (headlinez.news)
Discover more from Archyworldys
Subscribe to get the latest posts sent to your email.